Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives

Aberrant c-MET (Mesenchymal–Epithelial Transition) signaling contributes to cancer cell development, proliferation, and metastases of non-small cell lung cancer (NSCLC). MET exon 14 (METex14) skipping mutation is noted in approximately 4% of NSCLC cases and is targetable with the recently approved t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraser, Madison, Seetharamu, Nagashree, Diamond, Matthew, Lee, Chung-Shien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629434/
https://www.ncbi.nlm.nih.gov/pubmed/37941971
http://dx.doi.org/10.2147/CMAR.S386799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629434/
https://www.ncbi.nlm.nih.gov/pubmed/37941971
http://dx.doi.org/10.2147/CMAR.S386799

Ejemplares similares